A rumor regarding Ascendis Pharma (ASND) was highlighted in Ben Harrington’s M&A-focused Betaville blog, contacts tell The Fly.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma price target raised to $256 from $254 at Stifel
- Ascendis Pharma Grants Employee Warrants to Strengthen Market Position
- Positive Outlook for Ascendis Pharma: Buy Rating Despite PDUFA Delay
- Ascendis Pharma Faces FDA Delay for TransCon CNP Approval
- Positive Outlook on Ascendis Pharma Despite PDUFA Date Extension for TransCon CNP